Fresenius Medical Care stock costs EUR 37.64, market cap EUR 10.0 billion

Published on 10/09/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bernstein kept a EUR 44.65 target on October 8, 2026. Fresenius Medical Care stock costs EUR 37.64 on October 9, 2026 after EUR 37.21, plus 1.16 percent.

Key points in brief

Fresenius Medical Care stock traded at EUR 37.64 at Lang & Schwarz on October 9, 2026, plus 1.16 percent versus EUR 37.21.
The company has a EUR 10.0 billion market capitalization and a P/E ratio of 11.30.
Bernstein maintained Hold and a EUR 44.65 target on October 8, 2026.
Fresenius Medical Care is scheduled to report third-quarter 2026 results on November 3, 2026.

Trading-Floor mit großen Bildschirmen, die Xetra- und MDAX-Kurscharts der Gesundheitsbranche zeigen — Börsen-Editorial zeigt Trading-Floor mit Xetra- und MDAX-Charts, passend zu Fresenius Medical Care AG DE0005785802, Illustration mit AI erstellt.

Fresenius Medical Care stock was trading at EUR 37.64 at Lang & Schwarz on October 9, 2026 at 3:21 p.m. CEST, up 1.16 percent versus the prior close of EUR 37.21. The company had a market capitalization of EUR 10.0 billion on the same date, giving investors a market-value anchor alongside the intraday quotation.

Stock sits within yearly range

The stock's 52-week range runs from EUR 34.57 to EUR 47.86, according to the October 9 market snapshot. The current price is EUR 13.29 below the high, a 27.77 percent gap calculated in the same currency, while it stands EUR 3.07 above the low.

The price remains close to the lower part of that annual band rather than the upper boundary. Its P/E ratio is 11.30 and the trailing dividend yield is 0.04 percent, placing the valuation figures beside the range rather than treating the share price as a standalone signal.

Analyst target stays above price

Markets Insider reported on October 8, 2026 that Bernstein analyst Susannah Ludwig maintained a Hold rating and set a EUR 44.65 price target. That target lies 18.63 percent above the Lang & Schwarz price, using EUR 37.64 as the comparison value.

A separate Börse Express report dated October 1, 2026 said Berenberg cut its target from EUR 60.00 to EUR 42.00 and expected EUR 110.00 million of one-time costs in the third quarter from the China restructuring. The report also identified November 3, 2026 as the date for the next quarterly results.

Comparison with peers

Fresenius Medical Care: plus 1.16 percent, P/E 11.30, market capitalization EUR 10.0 billion
DaVita (NYSE, USD): plus 0.14 percent, P/E 15.56, market capitalization USD 11.4 billion
Envista Holdings (NYSE, USD): minus 1.39 percent, P/E 39.17, market capitalization USD 3.7 billion

Next results on November 3

Fresenius Medical Care's investor calendar lists November 3, 2026 for the third-quarter earnings release and conference call, followed by the quarterly financial report on November 6, 2026. The calendar also places the third-quarter reporting quiet period from October 20 through November 2, 2026, making the upcoming release the next dated company checkpoint.

Price and investor context

At EUR 37.64, the stock is EUR 7.02 below the Bernstein target and EUR 4.36 below the Berenberg target, although those analyst figures reflect different rating dates and methodologies. The combination of a 27.77 percent distance from the yearly high, a P/E of 11.30 and a 0.04 percent dividend yield gives the November results a clear numerical reference point.

The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.